Navigation Links
Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
Date:9/24/2010

tary partnerships in this expanding drug class based on its Peptelligence™ platform.  Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence.  Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Unigene's technologies have extensive clinical and partner validation.  The Company's first product to market, Fortical®, a nasal calcitonin product, received FDA approval in 2005 and is marketed in the U.S. by Upsher-Smith for the treatment of postmenopausal osteoporosis.  Pivotal clinical programs include an oral calcitonin licensed to Tarsa Therapeutics, now in Phase 3 testing for the treatment of osteoporosis.  Other validating relationships include an oral parathyroid hormone nearing Phase 2 and licensed to GlaxoSmithKline.  In addition, Unigene has a manufacturing license agreement with Novartis, which is completing three Phase 3 studies of oral calcitonin for the treatment of osteoporosis and osteoarthritis.

For more information about Unigene, please visit http://www.unigene.com.  For information about Fortical, please visit http://www.fortical.com.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements, including with respect to clinical studies of one of our licensees. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to
'/>"/>

SOURCE Tarsa Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PTC Therapeutics Awarded $1.6 Million FDA Orphan Drug Grant to Support an Ongoing Phase 3 Study in Cystic Fibrosis
2. Talecris Biotherapeutics GmbH Awards Winners of the 7th Annual European ALTA Research Fellowship at 2010 ERS Meeting
3. Cell Therapeutics, Inc. Reports Outcome of Annual Meeting of Shareholders
4. Protalix BioTherapeutics Names Tzvi Palash Chief Operating Officer
5. Reportlinker Adds Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange
8. Reportlinker Adds Protein Kinase Therapeutics in Oncology - Where to Commercialize?
9. Trius Therapeutics Reports 2010 Second Quarter Results
10. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
11. MabVax Therapeutics Receives Small Business Innovation Research Program Award from the National Cancer Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Whitehouse Laboratories is pleased to ... Parenteral Drug Association (PDA) to host a unique ... closure integrity testing. This lecture/laboratory course will examine the ... detailed in the recently proposed revision to USP 1207 ... will span container closure integrity testing (leak testing) critical ...
(Date:9/29/2014)... CA (PRWEB) September 30, 2014 ... million burn injuries require medical attention. In the ... brings serious complications to battlefield medical care. More ... Iraq and Afghanistan. Burn wounds heal slowly, remain ... can be excessive, physically debilitating and functionally damaging. ...
(Date:9/29/2014)... 29, 2014  Ten of the most highly-respected ... repair, regeneration, allograft reconstruction and research and development, ... gathered to discuss the future of cartilage regeneration ... Medicine symposium, Cartilage Regeneration: State of the ... Biosurgery, Minced Juvenile Allograft, and State of the ...
(Date:9/29/2014)... global challenges in food security, emerging diseases and ... study published online in Science Express ... University of Arizona College of Agriculture and Life ... team of nine scientists has reviewed progress in ... medicine and environmental management using approaches that consider ...
Breaking Biology Technology:Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4Faster Healing with Fewer Scars 2World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3Evolutionary biology: It's not just for textbooks anymore 2Evolutionary biology: It's not just for textbooks anymore 3
... Delivers Solid Financial Performance While Building for the Future, ... GENZ ) today reported strong sales and profit growth ... commercial and clinical,programs., Revenue increased 25 percent to ... quarter. The increase was driven by,growth across all areas ...
... TORONTO, July 23 /PRNewswire-FirstCall/ - Roche,(SWX: ROG) and ... two,companies have signed a definitive agreement for Roche ... price of approximately C$191 million. ARIUS is,the developer ... identifies and selects antibodies based on their functional,ability ...
... of,Directors of BD (Becton, Dickinson and Company) (NYSE: ... per common share. The dividend will be,payable on September ... 2008.,The indicated annual dividend rate is $1.14 per share., ... medical technology company that develops,manufactures and sells medical devices, ...
Cached Biology Technology:Genzyme Reports Strong Second-Quarter Growth 2Genzyme Reports Strong Second-Quarter Growth 3Genzyme Reports Strong Second-Quarter Growth 4Genzyme Reports Strong Second-Quarter Growth 5Genzyme Reports Strong Second-Quarter Growth 6Genzyme Reports Strong Second-Quarter Growth 7Genzyme Reports Strong Second-Quarter Growth 8Genzyme Reports Strong Second-Quarter Growth 9Genzyme Reports Strong Second-Quarter Growth 10Genzyme Reports Strong Second-Quarter Growth 11Genzyme Reports Strong Second-Quarter Growth 12Genzyme Reports Strong Second-Quarter Growth 13Genzyme Reports Strong Second-Quarter Growth 14Genzyme Reports Strong Second-Quarter Growth 15Genzyme Reports Strong Second-Quarter Growth 16Genzyme Reports Strong Second-Quarter Growth 17Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics 2Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics 3Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics 4
(Date:9/30/2014)... of Ludwig-Maximilians-Universitaet (LMU) in Munich report that a ... more sensitive to chemotherapeutic drugs. They have also ... new target for anti-tumor agents. , Researchers ... Stephan Sieber of the Technische Universitt Mnchen have ... potential new weapon in the fight against malignant ...
(Date:9/30/2014)... Sept. 30, 2014  Spectra Automation, a ... the biotech and power generation industries, announced ... Bioprocess Manager, an easy-to-use and cost-effective data ... bioprocess development laboratories. Most ... and analyzer systems. Accessing and consolidating data ...
(Date:9/29/2014)... , coupled with a high-fat diet, may cause animals to ... mBio , the online open-access journal of the American Society ... Institute of Human Nutrition Potsdam-Rehbruecke in Nuthetal observed that mice ... weight when fed a high-fat diet. Mice that did not ... consuming a high-fat diet, and mice that had C. ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2Gut bacteria promote obesity in mice 2
... OKLAHOMA CITY After years of working toward this goal, ... to isolate cancer stem cells in tumors so they can ... A research team at the University of Oklahoma ... that a particular protein only appears in stem cells. Until ...
... after eating a slice of pepperoni pizza? A little heartburn, ... women in the U.S., enjoying that piece of pizza has ... pelvic pain. Spicy food -- as well as citrus, caffeine, ... and intensify the pain. Researchers had long believed the spike ...
... Asheville, NC The U.S. Forest Service Southern Research ... Economics of Forest Disturbances: Wildfires, Storms, and Invasive Species ... a synthesis of new approaches to understanding the economics ... Forest Disturbances is the first book of its ...
Cached Biology News:The pepperoni pizza hypothesis 2The pepperoni pizza hypothesis 3Book breaks new ground in the study of economics and forest threats management 2
CHIMAERIC HUMAN IgA2 ANTI NP...
ANTI NO-TRYPTOPHAN CONJUGATE...
... The Captivate magnetic separator ... be used in conjunction with ... C-21474, C-21476) or other magnetic ... most 96-well microplates. Cell Biology ...
Protein Phosphorylation...
Biology Products: